Top of page Skip navigation

    Network and connect with us


    Reserve your table or tickets today

We thank the following organisations for supporting the 2018 Gala Dinner



Abzena provides proprietary technologies and complementary services in the UK and US to enable the development and manufacture of biopharmaceuticals. 

The Group comprises Antitope, PacificGMP and PolyTherics, which between them have built a global customer base including the majority of the top 20 biopharmaceutical companies as well as many large and small biotech companies and leading academic research institutions.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.

provides contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.

Abzena has its main operations in Cambridge, UK and in San Diego, CA, USA. The shares of Abzena plc are quoted on the AIM segment of the London Stock Exchange under the symbol ABZA.

Arthur J Gallagher

The rewards can be tremendous – the impacts global.  However pioneering, the new and the radical comes at significant cost and enormous, relentless risk.  That’s why it’s good to have a life sciences insurance broking partner who understands the intricate ethical, regulatory and commercial pressures you face.

Arthur J. Gallagher is one of the UK’s leading commercial insurance brokers for the life sciences sector, which now include the combined expertise of specialist advisors that were previously associated with OAMPS Special Risks and Oval Insurance Brokers.

Our capability, commitment and professional connections enable us to rationalise your risk, innovatively and cost effectively.  
Whether you’re a start-up or a multinational, whether you’re operating at home or entering new territories, we help to prepare a range of high performance, bespoke insurance covers that protect you today and anticipate the risks of tomorrow – ensuring peace of mind at the moment of truth.  Our exceptional relationships with specialist insurers deliver bespoke risk transfer programmes that may include: Directors’ and Officers’ Liability; Clinical Trials Liability; Products and Services Liability; Property coverage, whether premises based or in Transit; Loss of Income and Unproductive R&D Expenditure Protection; Supply Chain risks; Defence and/or Pursuit of Intellectual Property infringement; Professional Indemnity.



Funded by Government, BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond by helping society to meet major challenges, including green energy, food security and healthier, longer lives.

Industrial Biotechnology and Bioenergy (IBBE) is one of BBSRC’s three strategic priority areas. BBSRC is actively working with partners to build a thriving IBBE sector and last year invested £50.4 million into research and innovation around energy, chemicals and biopharmaceuticals. Through BBSRC’s Networks in Industrial Biotechnology and Bioenergy (BBSRC NIBB) more than 600 companies are currently engaged in collaborative working with over 2,600 academics to find new approaches to tackle research challenges, translate research and deliver key benefits in IBBE.



With more than 35 years representing life sciences clients, Cooley has been at the forefront working alongside leading life sciences companies across the globe. Our clients include both high-growth and mature companies as well as entrepreneurs, venture capitalists and financial institutions. We represent more than 1,200 life sciences companies and medical technologies companies worldwide. 

Cooley has been involved with hundreds of transactions across various technologies and stages of product development and are widely recognized as best-in-class in handling corporate partnering and licensing transactions. We have handled more than 1,000 M&A transactions since 2010 and understand unique structuring issues for life sciences companies, including milestone structures, contingent value rights and option structures. We are the #1 ranking firm in the representation of U.S. issuer-side life science IPOs since 2000 per IPO Vital Signs.  Our team includes leading regulatory lawyers and over 70 life sciences patent lawyers and professionals.


Helping shape a new age of healthcare

There is no other life sciences company quite like GE Healthcare’s Life Sciences business.  Part of GE Healthcare, we are a $4 billion business of 11,500 people in over 100 countries, at work enabling a new era in medicine.  We have the agility and unmatched global capabilities that come with being part of a company that continually pushes the frontiers of science and technology.

For more than 60 years, GE Healthcare Life Sciences has supported the development and use of new therapies, helping accelerate the journey from biological understanding to clinical therapy. At GE Healthcare Life Sciences, we believe that the practice of science and medicine is at a turning point; we are on the cusp of understanding biological and genetic mysteries and uncovering treatments for complex diseases that would have been unthinkable just a few years ago. We are supporting the  development of more personalized and targeted therapies by advancing cell therapy. We are helping healthcare practitioners gain new understanding of the body and enabling earlier and more precise diagnosis of disease with our imaging technologies. And as the development of molecules and medicines becomes more complex, we are reimagining the processes and manufacturing operations that make large scale biopharmaceutical production possible.

Headquartered in the United Kingdom, we provide expertise and tools in biotechnology, life sciences and clinical diagnostics, supporting fields from basic cell, protein and drug discovery research, to large-scale biopharmaceutical manufacturing, and diagnostic imaging in diseases such as cancer, heart disease and neurological disorders. 


Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and in vivo models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c1,600 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.


Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need.

Summit is a UK based drug discovery and development Company focused on producing innovative medicines to treat areas of high unmet medical need. Summit is developing high-quality, differentiated programmes that seek to provide the Company with the opportunity of maximising their therapeutic and commercial potential for the benefit of patients and shareholders.

Summit’s current therapeutic focus is on the rare disease Duchenne muscular dystrophy (DMD) and the infectious disease caused by the bacteria C. difficile.
Summit has established leadership positions in these two therapy areas that are enhanced through formation of strong partnerships with a range of leading academic groups, clinicians and community advocacy foundations.


VWR (NASDAQ: VWR), headquartered in Radnor, Pennsylvania, is a global independent provider of product and service solutions to laboratory and production customers. With sales in excess of $4.5 billion in 2016, VWR enables science for customers in the pharmaceutical, biotechnology, industrial, education, government and healthcare industries.  With more than 160 years of experience, VWR has cultivated a value proposition delivering product choice, operational excellence and differentiated services to improve our customers’ productivity from research to production. 

VWR’s differentiated services provide innovative, flexible and customized solutions from scientific research services to custom-manufactured chemical blends. Our dedicated team of more than 10,200 associates is focused on supporting scientists, medical professionals and production engineers to achieve their goals.